Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of Zilurgisertib in Renal Impairment
NCT05099445Phase 1Completed
- Sponsor
- Incyte
- Start
- Dec 2021
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of zilurgisertib in fibrodysplasia ossificans progressiva (FOP) and anemia (5 arms), sponsored by Incyte. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve from time 0 to last measurable concentration and 1 more. Started Dec 2021; status: completed.
02
Drugs
zilurgisertib
03
Conditions
fibrodysplasia ossificans progressiva (FOP)anemia
Beyond the preview
Go deeper on NCT05099445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05099445.